NOVABAY PHARMACEUTICALS

Shareholders of NovaBay Pharmaceuticals approved several proposals at a special meeting, including a new certificate of incorporation, an increase in authorized common stock from 1.5 billion to 5 billion shares, the removal of the ban on written shareholder consents and the inclusion of Delaware indemnification provisions. They also approved the issuance of a total of about 843 million common shares upon exercise of pre-funded warrants from private placements and adopted an Equity Incentive Plan 2026. The company had previously announced a private placement of pre-funded warrants for $134 million, an ATM distribution agreement for $100 million and a 1-for-5 reverse stock split; the stock was trading at $1.27 with a year-to-date loss of 95.5%. All information is from the SEC filing (Form 8‑K). » Plus sur de.investing.com

NovaBay Pharmaceuticals has completed a 1:5 reverse stock split effective 4:15 p.m. Eastern Time; the common stock will trade on a split-adjusted basis on the NYSE American at the opening of trading and will retain the ticker NBY. Under the split, every five shares were combined into one, fractional shares were settled by issuing additional whole shares, and the par value and authorized share count remain unchanged. The company also entered an at-the-market distribution agreement for $100 million with Virtu Americas and a private placement of $134 million in pre-funded warrants that enable the purchase of more than 837 million common shares. The board and shareholders had previously approved the split; an extraordinary general meeting is scheduled for March 12, 2026, to vote on the issuance of shares in connection with the pre-funded warrants. » Plus sur de.investing.com

NovaBay Pharmaceuticals’ audit committee has appointed CBIZ CPAs, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and reports no prior consultations or disagreements with CBIZ. The company has scheduled an extraordinary general meeting for March 12, 2026, at which, among other items, the issuance of common shares upon exercise of prepaid warrants is to be approved. NovaBay also announced an at-the-market agreement with Virtu Americas LLC for up to $100 million and a private placement of prepaid warrants with investors including R01 Fund LP and Framework Ventures IV L.P., expected to generate approximately $134 million in gross proceeds; the warrants were priced at $0.17 and are exercisable in tranches at $0.01 per share. » Plus sur de.investing.com